This request for proposals is open to projects that focus on therapy optimization in pediatric blood cancers that aim to minimize both short- and long-term treatment-associated toxicities. 

Traditional treatments for pediatric blood cancer often include chemotherapy, radiation and stem cell transplant which can have significant short-term and long-term consequences on the developing body of a child. There is a critical unmet need to reduce the burden of toxicity caused by the current standard of care while maintaining efficacy.

Research Topic

This RFP welcomes clinical trials focused on therapy optimization in all types of pediatric blood cancers, such as new combination therapy, reduction of chemotherapy by integrating immunotherapy, and reduction in intensity or duration of maintenance therapy.

We encourage interventional clinical trials (Phase I, II, or III) that include measurements of biomarkers to drive treatment decision-making and to assess the impact of an intervention (e.g., minimal residual disease). This should help to correlate optimization or de-escalation of treatment while maintaining efficacy.

Additionally, interventional clinical trials that focus on novel, less-toxic, targeted agents and immunotherapies, which might improve outcomes and decrease toxicity compared to current regimens, will also be considered.

DEADLINE FOR SUBMISSION OF LOI: 22 NOVEMBER 2024

For further information visit: https://www.risingtide-foundation.org/clinical-cancer-research-therapy-optimization-pediatric-blood-cancer/